📊 SEPN Key Takeaways
Is Septerna, Inc. (SEPN) a Good Investment?
Septerna demonstrates exceptional financial health with strong balance sheet (381.9M equity, zero long-term debt), positive free cash flow of 109.7M, and extraordinary revenue growth of 4174% YoY, indicating successful product commercialization. However, significant operating losses (-148% operating margin) and negative net income of 48.9M require demonstrated path to profitability as the company scales revenue.
Why Buy Septerna, Inc. Stock? SEPN Key Strengths
- Exceptional YoY revenue growth of 4174% indicates successful product launch and strong market adoption
- Very strong balance sheet with 381.9M stockholders equity, 120.7M cash, and zero long-term debt
- Positive free cash flow of 109.7M despite operating losses demonstrates underlying business viability and operational efficiency
- Excellent liquidity with 4.73x current ratio provides substantial financial flexibility and operational runway
- Low capital intensity (518K CapEx) enables focus on commercialization and profitability improvement
SEPN Stock Risks: Septerna, Inc. Investment Risks
- Significant operating losses (-148% operating margin) and negative net income require demonstrated path to profitability
- Early-stage commercialization risk: revenue sustainability depends on product demand persistence and competitive dynamics
- Operating expense structure appears misaligned with current revenue levels; cost control critical for margin improvement
- Gross margin data unavailable - key metric for assessing product-level economics and pricing power in pharma
- Uncertainty regarding sustainability of exceptional growth rates and achievement of unit economics at scale
Key Metrics to Watch
- Operating margin and net margin trajectory as revenue scales and cost structure optimizes
- Gross margin percentage and product-level unit economics to assess true profitability potential
- Free cash flow sustainability and cash runway duration given current burn rate
- Quarterly revenue growth rate deceleration or acceleration to confirm commercialization phase
- Operating expense ratio as percentage of revenue and timeline to operating profitability
Septerna, Inc. (SEPN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 238.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 4.73x current ratio provides a solid financial cushion.
SEPN Profit Margin, ROE & Profitability Analysis
SEPN vs Healthcare Sector: How Septerna, Inc. Compares
How Septerna, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Septerna, Inc. Stock Overvalued? SEPN Valuation Analysis 2026
Based on fundamental analysis, Septerna, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Septerna, Inc. Balance Sheet: SEPN Debt, Cash & Liquidity
SEPN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Septerna, Inc.'s revenue has grown significantly by 4,175% over the 5-year period, indicating strong business expansion. The most recent EPS of $-7.26 indicates the company is currently unprofitable.
SEPN Revenue Growth, EPS Growth & YoY Performance
SEPN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $176.0K | $8.2M | $0.18 |
| Q2 2025 | $119.0K | -$14.2M | $-0.56 |
| Q1 2025 | $219.0K | -$14.2M | $-0.49 |
| Q3 2024 | $33.0K | -$9.2M | $-5.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Septerna, Inc. Dividends, Buybacks & Capital Allocation
SEPN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Septerna, Inc. (CIK: 0001984086)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SEPN
What is the AI rating for SEPN?
Septerna, Inc. (SEPN) has an AI rating of BUY with 67% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SEPN's key strengths?
Claude: Exceptional YoY revenue growth of 4174% indicates successful product launch and strong market adoption. Very strong balance sheet with 381.9M stockholders equity, 120.7M cash, and zero long-term debt.
What are the risks of investing in SEPN?
Claude: Significant operating losses (-148% operating margin) and negative net income require demonstrated path to profitability. Early-stage commercialization risk: revenue sustainability depends on product demand persistence and competitive dynamics.
What is SEPN's revenue and growth?
Septerna, Inc. reported revenue of $46.0M.
Does SEPN pay dividends?
Septerna, Inc. does not currently pay dividends.
Where can I find SEPN SEC filings?
Official SEC filings for Septerna, Inc. (CIK: 0001984086) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SEPN's EPS?
Septerna, Inc. has a diluted EPS of $-1.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SEPN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Septerna, Inc. has a BUY rating with 67% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is SEPN stock overvalued or undervalued?
Valuation metrics for SEPN: ROE of -12.8% (sector avg: 15%), net margin of -106.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SEPN stock in 2026?
Our dual AI analysis gives Septerna, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SEPN's free cash flow?
Septerna, Inc.'s operating cash flow is $110.2M, with capital expenditures of $518.0K. FCF margin is 238.7%.
How does SEPN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -106.4% (avg: 12%), ROE -12.8% (avg: 15%), current ratio 4.73 (avg: 2).